Technical Analysis for CU6 - Clarity Pharmaceuticals Ltd
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | -4.86% | |
| Lower Bollinger Band Walk | Weakness | -4.86% | |
| Below Lower BB | Weakness | -4.86% |
| Alert | Time |
|---|---|
| Down 5% | 2 days ago |
| Fell Below Previous Day's Low | 3 days ago |
| Down 3% | 3 days ago |
| Down 2% | 3 days ago |
| Down 1% | 3 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product is SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Imaging Clinical Medicine Cancers Medicinal Radiochemistry Prostate Cancer Radiopharmaceuticals Treatment Of Cancer Personalized Medicine
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Imaging Clinical Medicine Cancers Medicinal Radiochemistry Prostate Cancer Radiopharmaceuticals Treatment Of Cancer Personalized Medicine
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.975 |
| 52 Week Low | 1.26 |
| Average Volume | 1,862,993 |
| 200-Day Moving Average | 5.237 |
| 50-Day Moving Average | 7.344 |
| 20-Day Moving Average | 6.841 |
| 10-Day Moving Average | 6.624 |
| Average True Range | 0.441 |
| RSI (14) | 31.51 |
| ADX | 19.92 |
| +DI | 15.069 |
| -DI | 34.793 |
| Chandelier Exit (Long, 3 ATRs) | 6.356 |
| Chandelier Exit (Short, 3 ATRs) | 6.934 |
| Upper Bollinger Bands | 7.890 |
| Lower Bollinger Band | 5.792 |
| Percent B (%b) | -0.05 |
| BandWidth | 30.671 |
| MACD Line | -0.315 |
| MACD Signal Line | -0.178 |
| MACD Histogram | -0.1366 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.370 | ||||
| Resistance 3 (R3) | 6.423 | 6.247 | 6.255 | ||
| Resistance 2 (R2) | 6.247 | 6.071 | 6.220 | 6.217 | |
| Resistance 1 (R1) | 5.963 | 5.962 | 5.875 | 5.910 | 6.178 |
| Pivot Point | 5.787 | 5.787 | 5.743 | 5.760 | 5.787 |
| Support 1 (S1) | 5.503 | 5.611 | 5.415 | 5.450 | 5.182 |
| Support 2 (S2) | 5.327 | 5.502 | 5.300 | 5.143 | |
| Support 3 (S3) | 5.043 | 5.327 | 5.105 | ||
| Support 4 (S4) | 4.990 |
